Lingmin He, MD
Ophthalmology · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 37
- 10 carriers
- Office
- 1
Offices
1 location · Retinal Diagnostic Center A Medical Corporation · 6 clinicians in this group
Plans that list them
37 plans · 10 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. He’s office at (408) 559-0666 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
37 of 37 plans
| Advantage Care (HMO) | Align Senior Care | Listed | Oct 1, 2026 |
| Premier Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Senior Care (HMO I-SNP) | Align Senior Care | Listed | Oct 1, 2026 |
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
California Medical Board record
Licence A118105 · Current
Licensed to practise in California · since 2011 · expires 2027-06-30 · Stanford University School of Medicine.
Matched on the licence number without its letter prefix; check the name before relying on it.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$2,764,572
Medicare paid this office $2,764,572 for 916 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, faricimab-svoa, 0.1 mg | 261 | $1,672,997 | None |
| Injection, avacincaptad pegol, 0.1 mg | 29 | $179,568 | None |
| Injection of drug into eye | 339 | $151,335 | $102 |
| Injection, ranibizumab, 0.1 mg | 93 | $143,323 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 14 | $115,673 | None |
See all 17 services
| Injection, faricimab-svoa, 0.1 mg | 261 | $1,672,997 | None |
| Injection, avacincaptad pegol, 0.1 mg | 29 | $179,568 | None |
| Injection of drug into eye | 339 | $151,335 | $102 |
| Injection, ranibizumab, 0.1 mg | 93 | $143,323 | None |
| Injection, pegcetacoplan, intravitreal, 1 mg | 14 | $115,673 | None |
| Established patient complete exam of visual system | 736 | $111,702 | $101 |
| Imaging of retina | 883 | $83,208 | $35 |
| Established patient problem focused exam of visual system | 346 | $49,505 | $79 |
| New patient visit (45+ min) | 172 | $21,630 | $126 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 20 | $21,471 | $1,074 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 122 | $20,158 | $160 |
| 2d ultrasound scan of eye tissue and structures | 85 | $6,931 | $43 |
| Photography of the retina | 160 | $5,172 | $30 |
| Removal of recurring cataract in lens capsule by stab incision | 17 | $4,383 | $258 |
| Destruction of leaking blood vessels of retina using laser | 11 | $3,576 | $298 |
| Compounded drug, not otherwise classified | 24 | $2,540 | None |
| New patient visit (60+ min) | 11 | $1,937 | $176 |
Procedures Medicare counted
| Cataract surgery | 19 | More than 43% of doctors who do this |
Who their Medicare patients are
916 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 22% · Women 59% · Also on Medicaid 26% · Health risk score 1.40. Above the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 38% · Chronic kidney disease 25% · Coronary heart disease 22% · Atrial fibrillation 17% · Heart failure 14% · Depression 14% · Cancer 12% · COPD 9% · Dementia 7% · Stroke 6%.
The office billed $9,312,837, Medicare allowed $3,525,775 and paid $2,764,572; for 82,545 services of 55 kinds; $2,214,956 of it was for drugs given in the office and $549,616 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 916 | 82,545 | 77 | 1.40 | $9,312,837 | $2,764,572 |
| 2023 | 909 | 35,547 | 77 | 1.42 | $7,674,039 | $2,101,406 |
| 2022 | 533 | 6,374 | 77 | 1.39 | $3,201,064 | $875,767 |
| 2021 | 590 | 6,177 | 77 | 1.43 | $3,863,351 | $1,119,752 |
| 2020 | 381 | 4,237 | 76 | 1.63 | $2,576,879 | $739,658 |
| 2019 | 504 | 4,800 | 76 | 1.63 | $2,493,372 | $672,016 |
| 2018 | 395 | 3,287 | 77 | 1.28 | $1,756,901 | $457,712 |
| 2017 | 252 | 1,726 | 76 | 1.42 | $864,865 | $206,146 |
| 2016 | 159 | 506 | 73 | 1.50 | $256,060 | $50,227 |
| 2015 | 126 | 184 | 73 | 1.45 | $167,336 | $24,334 |
| 2014 | 57 | 72 | 71 | 1.22 | $55,014 | $9,188 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Injection, faricimab-svoa, 0.1 mg | 123 | $719,520 | None |
| Injection, ranibizumab, 0.1 mg | 158 | $445,686 | None |
| Injection, aflibercept, 1 mg | 76 | $307,048 | None |
| Injection of drug into eye | 335 | $141,683 | $105 |
| Established patient complete exam of visual system | 659 | $102,162 | $107 |
| Imaging of retina | 854 | $81,017 | $36 |
| Established patient problem focused exam of visual system | 353 | $61,240 | $82 |
| New patient visit (45+ min) | 232 | $29,998 | $129 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 185 | $25,075 | $136 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 20 | $23,987 | $1,090 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 13 | $21,731 | $1,207 |
| Compounded drug, not otherwise classified | 79 | $12,625 | None |
| Photography of the retina | 224 | $7,432 | $31 |
| 2d ultrasound scan of eye tissue and structures | 91 | $6,431 | $44 |
| Photocoagulation treatment to prevent detachment of retina | 19 | $4,716 | $236 |
| Destruction of leaking blood vessels of retina using laser | 14 | $4,238 | $283 |
| New patient visit (60+ min) | 18 | $3,268 | $182 |
| Injection of drug or substance into membrane covering eyeball | 13 | $733 | $43 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 13 | $122 | None |
2022: 14 services
| Injection, ranibizumab, 0.1 mg | 109 | $310,116 | None |
| Injection, aflibercept, 1 mg | 44 | $186,439 | None |
| Injection of drug into eye | 215 | $63,670 | $107 |
| Unclassified biologics | 16 | $51,182 | None |
| Established patient complete exam of visual system | 352 | $46,902 | $101 |
| Injection, faricimab-svoa, 0.1 mg | 18 | $37,600 | None |
| Imaging of retina | 474 | $36,186 | $36 |
| Established patient problem focused exam of visual system | 222 | $31,074 | $80 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 105 | $13,625 | $125 |
| New patient visit (45+ min) | 85 | $10,518 | $124 |
| Compounded drug, not otherwise classified | 58 | $8,247 | None |
| Photography of the retina | 122 | $3,910 | $31 |
| 2d ultrasound scan of eye tissue and structures | 50 | $3,175 | $42 |
| Extended exam of the back part of the eye with retinal drawing | 14 | $307 | $22 |
2021: 14 services
| Injection, ranibizumab, 0.1 mg | 117 | $488,817 | None |
| Injection, aflibercept, 1 mg | 69 | $280,206 | None |
| Injection of drug into eye | 245 | $81,895 | $111 |
| Established patient complete exam of visual system | 325 | $49,619 | $109 |
| Imaging of retina | 511 | $42,102 | $38 |
| Established patient problem focused exam of visual system | 257 | $36,422 | $85 |
| New patient visit (45+ min) | 144 | $21,238 | $147 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 136 | $16,368 | $116 |
| Compounded drug, not otherwise classified | 75 | $10,378 | None |
| Removal of eye fluid (vitreous) between lens and retina | 12 | $9,851 | $758 |
| Photography of the retina | 201 | $7,278 | $32 |
| Destruction of leaking blood vessels of retina using laser | 13 | $4,834 | $302 |
| 2d ultrasound scan of eye tissue and structures | 60 | $4,778 | $46 |
| Return visit (30+ min) | 15 | $1,074 | $67 |
2020: 14 services
| Injection, ranibizumab, 0.1 mg | 61 | $307,366 | None |
| Injection, aflibercept, 1 mg | 42 | $177,036 | None |
| Injection of drug into eye | 134 | $46,322 | $100 |
| Established patient complete exam of visual system | 247 | $32,865 | $104 |
| Established patient problem focused exam of visual system | 159 | $24,493 | $82 |
| Imaging of retina | 275 | $22,097 | $37 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 12 | $19,575 | $1,305 |
| Photography of the retina | 237 | $11,804 | $40 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 102 | $11,506 | $104 |
| New patient visit (45+ min) | 81 | $11,420 | $141 |
| Compounded drug, not otherwise classified | 62 | $9,316 | None |
| Removal of eye fluid (vitreous) between lens and retina | 11 | $7,617 | $692 |
| Destruction of leaking blood vessels of retina using laser | 12 | $5,354 | $335 |
| 2d ultrasound scan of eye tissue and structures | 41 | $3,067 | $49 |
2019: 20 services
| Injection, aflibercept, 1 mg | 59 | $267,768 | None |
| Injection, ranibizumab, 0.1 mg | 26 | $93,969 | None |
| Injection of drug into eye | 157 | $48,100 | $93 |
| Established patient problem focused exam of visual system | 226 | $36,470 | $80 |
| Established patient complete exam of visual system | 242 | $31,440 | $108 |
| Imaging of retina | 379 | $30,452 | $37 |
| New patient visit (45+ min) | 192 | $24,919 | $130 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 14 | $24,626 | $1,296 |
| Injection, bevacizumab, 10 mg | 95 | $14,417 | None |
| Photography of the retina | 259 | $14,078 | $47 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 13 | $13,709 | $1,055 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 116 | $11,140 | $89 |
| Examination of eye by ophthalmoscope with retinal drawing | 152 | $7,414 | $26 |
| Photocoagulation treatment to prevent detachment of retina | 13 | $6,641 | $511 |
| Destruction of leaking blood vessels of retina using laser | 11 | $5,287 | $311 |
| 2d ultrasound scan of eye tissue and structures | 44 | $3,444 | $56 |
| Examination of eye by ophthalmoscope with retinal drawing | 40 | $2,015 | $25 |
| Injection of drug or substance into membrane covering eyeball | 13 | $1,387 | $73 |
| Exam of the internal drainage system of eye | 12 | $355 | $24 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 12 | $92 | None |
2018: 16 services
| Injection, aflibercept, 1 mg | 26 | $113,868 | None |
| Injection, ranibizumab, 0.1 mg | 22 | $85,887 | None |
| Injection of drug into eye | 108 | $32,852 | $93 |
| New patient visit (45+ min) | 208 | $28,765 | $138 |
| Established patient problem focused exam of visual system | 159 | $24,408 | $81 |
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 15 | $22,982 | $1,277 |
| Established patient complete exam of visual system | 160 | $22,156 | $111 |
| Imaging of retina | 261 | $21,616 | $39 |
| Photography of the retina | 218 | $13,592 | $53 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 11 | $12,572 | $1,143 |
| Injection, bevacizumab, 10 mg | 77 | $12,007 | None |
| Exam of retinal blood vessels using a special camera after injection of a dye | 110 | $9,747 | $83 |
| Photocoagulation treatment to prevent detachment of retina | 17 | $9,584 | $504 |
| Examination of eye by ophthalmoscope with retinal drawing | 157 | $7,341 | $26 |
| 2d ultrasound scan of eye tissue and structures | 37 | $3,246 | $72 |
| Examination of eye by ophthalmoscope with retinal drawing | 30 | $1,214 | $23 |
2017: 14 services
| Injection, aflibercept, 1 mg | 16 | $58,293 | None |
| Injection of drug into eye | 73 | $16,755 | $93 |
| New patient visit (45+ min) | 86 | $11,758 | $137 |
| Established patient problem focused exam of visual system | 96 | $11,162 | $72 |
| Imaging of retina | 149 | $10,419 | $36 |
| Established patient complete exam of visual system | 73 | $9,639 | $113 |
| Injection, bevacizumab, 10 mg | 65 | $7,781 | None |
| Photography of the retina | 110 | $7,615 | $65 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 75 | $5,493 | $73 |
| Examination of eye by ophthalmoscope with retinal drawing | 117 | $5,487 | $25 |
| New patient complete exam of visual system | 43 | $4,300 | $100 |
| 2d ultrasound scan of eye tissue and structures | 24 | $3,065 | $85 |
| Examination of eye by ophthalmoscope with retinal drawing | 19 | $774 | $23 |
| Short return visit (20+ min) | 14 | $761 | $45 |
2016: 11 services
| New patient complete exam of visual system | 62 | $8,373 | $135 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 24 | $4,631 | $101 |
| Established patient problem focused exam of visual system | 31 | $2,637 | $78 |
| Examination of eye by ophthalmoscope with retinal drawing | 54 | $2,599 | $26 |
| Injection of drug into eye | 15 | $2,578 | $95 |
| Removal of eye fluid (vitreous) between lens and retina | 13 | $2,334 | $180 |
| Imaging of retina | 50 | $2,271 | $41 |
| Photography of the retina | 28 | $2,042 | $73 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 12 | $1,872 | $156 |
| Injection, bevacizumab, 10 mg | 13 | $1,304 | None |
| 2d ultrasound scan of eye tissue and structures | 11 | $1,257 | $84 |
2015: 7 services
| Complex repair of detached retina and drainage of eye fluid between lens and retina | 17 | $3,421 | $201 |
| Repair of detached retina with drainage and removal of eye fluid between lens and retina | 14 | $2,755 | $197 |
| Removal of membrane of retina | 15 | $2,341 | $156 |
| Removal of eye fluid (vitreous) between lens and retina | 17 | $2,247 | $118 |
| Removal of membrane of retina with removal of internal limiting membrane of retina | 12 | $1,869 | $156 |
| Established patient problem focused exam of visual system | 15 | $1,066 | $67 |
| Imaging of retina | 13 | $445 | $32 |
Medicaid work
$346,119 in 2024
Medicaid paid $346,119 for 3,049 billed services this clinician did in 2024, up to 120 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Injection, faricimab-svoa, 0.1 mg | 291 | $236,933 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 628 | $39,820 |
| Ranibizumab injection | 77 | $20,447 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,013 | $13,982 |
| Return visit (30+ min) | 100 | $8,463 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 321 | $8,224 |
| Injection, bevacizumab, 10 mg | 146 | $6,900 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 211 | $5,581 |
| New patient visit (45+ min) | 71 | $2,410 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 25 | $1,359 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 108 | $1,245 |
| OPH US DX B-SCAN | 58 | $754 |
| 2024 | 3,049 | 12 | 120 | $346,119 |
| 2023 | 3,671 | 12 | 130 | $255,210 |
| 2022 | 1,875 | 9 | 82 | $81,456 |
| 2021 | 1,843 | 9 | 82 | $90,904 |
| 2020 | 1,069 | 7 | 44 | $43,216 |
| 2019 | 1,293 | 9 | 42 | $46,994 |
| 2018 | 327 | 5 | 36 | $13,310 |
See the largest Medicaid services in earlier years
2023
| Injection, faricimab-svoa, 0.1 mg | 59 | $72,557 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 708 | $50,821 |
| Ranibizumab injection | 122 | $39,810 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,157 | $20,207 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 447 | $19,680 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 387 | $15,170 |
| Injection, bevacizumab, 10 mg | 289 | $12,427 |
| New patient visit (45+ min) | 145 | $11,748 |
| Return visit (30+ min) | 47 | $4,225 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 63 | $3,705 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 171 | $3,392 |
| OPH US DX B-SCAN | 76 | $1,469 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 354 | $29,928 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 284 | $12,153 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 608 | $10,890 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 231 | $10,424 |
| Injection, bevacizumab, 10 mg | 172 | $9,657 |
| New patient visit (45+ min) | 31 | $3,075 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 117 | $2,641 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 29 | $1,755 |
| OPH US DX B-SCAN | 49 | $935 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 381 | $43,529 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 617 | $10,902 |
| Injection, bevacizumab, 10 mg | 191 | $10,228 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 248 | $10,183 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 230 | $9,198 |
| New patient visit (45+ min) | 36 | $2,652 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 105 | $2,434 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 17 | $1,302 |
| OPH US DX B-SCAN | 18 | $475 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 233 | $17,433 |
| Injection, bevacizumab, 10 mg | 120 | $6,499 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 344 | $6,492 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 155 | $4,615 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 115 | $3,798 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 87 | $3,669 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 15 | $710 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 245 | $20,975 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 199 | $7,575 |
| Injection, bevacizumab, 10 mg | 209 | $6,737 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 354 | $5,089 |
| New patient visit (45+ min) | 55 | $3,294 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 89 | $1,973 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 108 | $740 |
| FLUORESCEIN ANGRPH W/MULTIFRAME IMG I&R UNI/BI | 12 | $473 |
| Ophthalmoscopy, extended, with retinal drawing (eg, for retinal detachment, melanoma), with interpretation and report; initial | 22 | $137 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 52 | $7,172 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 181 | $2,777 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 44 | $1,868 |
| Injection, bevacizumab, 10 mg | 34 | $1,494 |
| Patient screened for tobacco use and identified as a tobacco non-user | 16 | $0 |
Drugs they prescribed that Part D paid
$18,500
Pharmacies billed $18,500 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
107 generic and 99 brand-name prescriptions · $18,500 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 70 | $3,194 | $46 |
| Ketorolac Tromethamine | 20 | $570 | $28 |
| Dorzolamide-Timolol | 18 | $257 | $14 |
| Brimonidine | 22 | $118 | $5 |
| Latanoprost | 15 | $50 | $3 |
Year by year
| 2024 | 206 | 91 | None | 48% | $18,500 |
| 2023 | 232 | 95 | None | 39% | $18,913 |
| 2022 | 138 | 56 | 0% (0) | 42% | $11,869 |
| 2021 | 157 | 67 | None | 34% | $9,378 |
| 2020 | 126 | 61 | None | 44% | $9,376 |
| 2019 | 165 | 60 | None | 51% | $14,938 |
| 2018 | 145 | 58 | 0% (0) | 51% | $10,502 |
| 2017 | 100 | 43 | None | 57% | $5,525 |
| 2016 | 305 | 111 | 13% (39) | None | $15,117 |
| 2015 | 286 | 106 | 14% (40) | 45% | $18,805 |
| 2014 | 131 | 58 | None | 58% | $9,405 |
| 2013 | 87 | 29 | None | 62% | $4,282 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Prednisolone Acetate | 51 | $2,984 | $59 |
| Ketorolac Tromethamine | 33 | $1,213 | $37 |
| Dorzolamide-Timolol | 24 | $619 | $26 |
| Brimonidine | 27 | $422 | $16 |
| Latanoprost | 15 | $246 | $16 |
| Timolol Maleate | 13 | $117 | $9 |
2022: 5 drugs
| Prednisolone Acetate | 27 | $1,524 | $56 |
| Ketorolac Tromethamine | 22 | $855 | $39 |
| Dorzolamide-Timolol | 19 | $498 | $26 |
| Brimonidine | 14 | $284 | $20 |
| Latanoprost | 16 | $139 | $9 |
2021: 5 drugs
| Ketorolac Tromethamine | 27 | $1,759 | $65 |
| Prednisolone Acetate | 28 | $1,631 | $58 |
| Dorzolamide-Timolol | 26 | $815 | $31 |
| Latanoprost | 20 | $241 | $12 |
| Brimonidine | 11 | $176 | $16 |
2020: 3 drugs
| Prednisolone Acetate | 31 | $1,891 | $61 |
| Dorzolamide-Timolol | 28 | $669 | $24 |
| Brimonidine | 12 | $285 | $24 |
2019: 3 drugs
| Prednisolone Acetate | 40 | $2,162 | $54 |
| Dorzolamide-Timolol | 21 | $573 | $27 |
| Ketorolac Tromethamine | 16 | $404 | $25 |
2018: 3 drugs
| Prednisolone Acetate | 47 | $3,226 | $69 |
| Ketorolac Tromethamine | 21 | $412 | $20 |
| Brimonidine | 14 | $341 | $24 |
2017: 1 drug
| Prednisolone Acetate | 37 | $1,657 | $45 |
2016: 7 drugs
| Prednisolone Acetate | 60 | $5,341 | $89 |
| Ketorolac Tromethamine | 25 | $1,038 | $42 |
| Erythromycin | 59 | $589 | $10 |
| Dorzolamide | 16 | $313 | $20 |
| Ciprofloxacin | 36 | $303 | $8 |
| Oxycodone | 38 | $220 | $6 |
| Latanoprost | 12 | $126 | $11 |
2015: 8 drugs
| Prednisolone Acetate | 62 | $6,780 | $109 |
| Ketorolac Tromethamine | 51 | $2,438 | $48 |
| Erythromycin | 46 | $618 | $13 |
| Brimonidine | 11 | $329 | $30 |
| Dorzolamide-Timolol | 11 | $286 | $26 |
| Oxycodone | 33 | $195 | $6 |
| Ciprofloxacin | 19 | $151 | $8 |
| Latanoprost | 11 | $94 | $9 |
2014: 4 drugs
| Travatan Z | 15 | $1,899 | $127 |
| Prednisolone Acetate | 25 | $1,782 | $71 |
| Ketorolac Tromethamine | 12 | $275 | $23 |
| Latanoprost | 13 | $149 | $11 |
2013: 3 drugs
| Travatan Z | 16 | $1,510 | $94 |
| Prednisolone Acetate | 13 | $176 | $14 |
| Timolol Maleate | 14 | $128 | $9 |
Money from drug and device companies
$5,941 in 2025
| 2025 | 7 | 32 | $4,050 | $5,941 |
| 2024 | 7 | 32 | None | $1,144 |
| 2023 | 9 | 18 | None | $736 |
| 2022 | 5 | 10 | None | $377 |
| 2021 | 2 | 6 | None | $123 |
| 2020 | 5 | 9 | None | $191 |
| 2019 | 6 | 19 | None | $527 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | Susvimo | $5,305 | 16 payments
|
| Apellis Pharmaceuticals | Syfovre | $324 | 9 payments
|
| Regeneron Pharmaceuticals | Eylea Hd | $131 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $98 | 3 payments
|
| Amgen | Tepezza | $32 | 1 payment
|
| Abbvie | Ozurdex | $30 | 1 payment
|
See all 32 published payments
| Genentech USA | Meals · 2025-12-15 | Susvimo | $29 |
| Apellis Pharmaceuticals | Meals · 2025-12-05 | Syfovre | $19 |
| Regeneron Pharmaceuticals | Meals · 2025-12-04 | Eylea Hd | $131 |
| Apellis Pharmaceuticals | Meals · 2025-12-02 | Syfovre | $7 |
| Mallinckrodt Hospital Products | Meals · 2025-11-10 | Acthar | $21 |
| Genentech USA | Meals · 2025-10-17 | Susvimo | $7 |
| Genentech USA | Meals · 2025-10-17 | Susvimo | $25 |
| Apellis Pharmaceuticals | Meals · 2025-10-14 | Syfovre | $28 |
| Amgen | Meals · 2025-10-06 | Tepezza | $32 |
| Genentech USA | Meals · 2025-09-30 | Vabysmo | $35 |
| Regeneron Healthcare Solutions | Meals · 2025-09-12 | Eylea Hd | $31 |
| Genentech USA | Meals · 2025-09-05 | Susvimo | $32 |
| Apellis Pharmaceuticals | Meals · 2025-08-29 | Syfovre | $32 |
| Genentech USA | Meals · 2025-08-15 | Susvimo | $36 |
| Genentech USA | Meals · 2025-07-29 | Susvimo | $102 |
| Genentech USA | Travel · 2025-07-29 | Susvimo | $329 |
| Genentech USA | Travel · 2025-07-29 | Susvimo | $313 |
| Genentech USA | Meals · 2025-07-29 | Susvimo | $194 |
| Genentech USA | Consulting · 2025-07-29 | Susvimo | $4,050 |
| Apellis Pharmaceuticals | Meals · 2025-07-29 | None | $144 |
| Apellis Pharmaceuticals | Meals · 2025-07-25 | Syfovre | $31 |
| Apellis Pharmaceuticals | Meals · 2025-07-10 | Syfovre | $11 |
| Genentech USA | Meals · 2025-06-27 | Susvimo | $32 |
| Regeneron Healthcare Solutions | Meals · 2025-05-13 | Eylea Hd | $32 |
| Genentech USA | Meals · 2025-05-06 | Susvimo | $30 |
| Genentech USA | Meals · 2025-04-25 | Vabysmo | $30 |
| Genentech USA | Meals · 2025-04-04 | Susvimo | $35 |
| Apellis Pharmaceuticals | Meals · 2025-04-01 | Syfovre | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-03-11 | Eylea Hd | $35 |
| Genentech USA | Meals · 2025-02-28 | Susvimo | $25 |
| Apellis Pharmaceuticals | Meals · 2025-01-31 | Syfovre | $28 |
| Abbvie | Meals · 2025-01-28 | Ozurdex | $30 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,144
| Astellas Pharma US | Izervay | $522 | 13 payments
|
| Genentech USA | Vabysmo | $173 | 6 payments
|
| Apellis Pharmaceuticals | Syfovre | $140 | 5 payments
|
| Abbvie | Ozurdex | $107 | 1 payment
|
| Regeneron Healthcare Solutions | Eylea Hd | $94 | 3 payments
|
| Mallinckrodt Hospital Products | Acthar | $60 | 2 payments
|
| Harrow Eye | Iheezo | $48 | 2 payments
|
2023: $736
| Genentech USA | Vabysmo | $186 | 7 payments
|
| Alcon Vision | Ngenuity | $140 | 1 payment
|
| Astellas Pharma US | None | $124 | 2 payments
|
| Biogen | None | $100 | 1 payment
|
| Abbvie | Ozurdex | $57 | 2 payments
|
| Apellis Pharmaceuticals | Syfovre | $44 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $30 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $30 | 1 payment
|
| Harrow Eye | Iheezo | $26 | 1 payment
|
2022: $377
| Alcon Vision | Ngenuity | $140 | 1 payment
|
| Genentech USA | Vabysmo | $136 | 5 payments
|
| Regeneron Healthcare Solutions | Eylea | $51 | 2 payments
|
| Apellis Pharmaceuticals | None | $29 | 1 payment
|
| Coherus Biosciences | Cimerli | $20 | 1 payment
|
2021: $123
| Genentech USA | Lucentis | $89 | 4 payments
|
| Regeneron Healthcare Solutions | Eylea | $34 | 2 payments
|
2020: $191
| Alimera Sciences | Iluvien | $67 | 3 payments
|
| Genentech USA | Lucentis | $48 | 2 payments
|
| Optos | P200dtx | $39 | 2 payments
|
| Carl Zeiss Meditec AG | None Specified | $19 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Visudyne | $18 | 1 payment
|
2019: $527
| Novartis Pharmaceuticals | Beovu | $280 | 12 payments
|
| Genentech | Lucentis | $154 | 2 payments
|
| Alimera Sciences | Iluvien | $31 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $24 | 1 payment
|
| Optos | P200dtx | $20 | 1 payment
|
| Genentech USA | Lucentis | $18 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1730405184
- Licence
- CA 118105California A118105: Current · expires 2027-06-30
- Trained
- Stanford University School of Medicine, 2010
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 3395 S Bascom Ave, Suite 140, Campbell, CA, 95008
- NPI first listed
- 2010-04-09
- NPI last updated
- 2016-09-27
This is when the NPI record was last certified, not a medical board exam.